Synthesis and Biological Evaluation of Reniochalistatins A-E and a Reniochalistatin E Analogue.
Identifieur interne : 000985 ( PubMed/Corpus ); précédent : 000984; suivant : 000986Synthesis and Biological Evaluation of Reniochalistatins A-E and a Reniochalistatin E Analogue.
Auteurs : Rong Zhou ; Yueguang Sun ; Hangbin Li ; Weili Long ; Xiaojian Liao ; Pengju Feng ; Shihai XuSource :
- ChemMedChem [ 1860-7187 ] ; 2018.
English descriptors
- KwdEn :
- Animals, Anti-Infective Agents (chemical synthesis), Anti-Infective Agents (chemistry), Anti-Infective Agents (pharmacology), Anti-Inflammatory Agents (chemical synthesis), Anti-Inflammatory Agents (chemistry), Anti-Inflammatory Agents (pharmacology), Antineoplastic Agents (chemical synthesis), Antineoplastic Agents (chemistry), Antineoplastic Agents (pharmacology), Cell Line, Tumor, Cyclization, Cyclooxygenase 1 (metabolism), Cyclooxygenase 2 (metabolism), Humans, Influenza A Virus, H3N2 Subtype (drug effects), Molecular Structure, Peptides, Cyclic (chemical synthesis), Peptides, Cyclic (chemistry), Peptides, Cyclic (pharmacology), Porifera (chemistry), Solid-Phase Synthesis Techniques, Structure-Activity Relationship.
- MESH :
- chemical , chemical synthesis : Anti-Infective Agents, Anti-Inflammatory Agents, Antineoplastic Agents, Peptides, Cyclic.
- chemical , chemistry : Anti-Infective Agents, Anti-Inflammatory Agents, Antineoplastic Agents, Peptides, Cyclic.
- chemical , metabolism : Cyclooxygenase 1, Cyclooxygenase 2.
- chemical , pharmacology : Anti-Infective Agents, Anti-Inflammatory Agents, Antineoplastic Agents, Peptides, Cyclic.
- chemistry : Porifera.
- drug effects : Influenza A Virus, H3N2 Subtype.
- Animals, Cell Line, Tumor, Cyclization, Humans, Molecular Structure, Solid-Phase Synthesis Techniques, Structure-Activity Relationship.
Abstract
The total synthesis of reniochalistatins A-E, along with a reniochalistatin E analogue (inverso-E) was successfully achieved through Fmoc-based solid-phase peptide synthesis and subsequent macrolactamization with PyBOP and DIEA. The biological activities of these reniochalistatins and a key linear peptide intermediate were systematically evaluated. Among these seven synthesized compounds, linear reniochalistatin B was found to have potent activity against several cancer cell lines not shown by the cyclic reniochalistatin B counterpart. In addition, linear reniochalistatin B was found to have antitubercular activity (IC50 =1.4 μm). Inverso-E possesses increasing cytotoxicity against the HeLa and LNCaP cell lines after simple alternation of the sequence of amino acids in reniochalistatin E. The results of these studies provide a feasible method to further investigate the structure-activity relationships (SARs) of reniochalistatins A-E.
DOI: 10.1002/cmdc.201800529
PubMed: 30102451
Links to Exploration step
pubmed:30102451Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Synthesis and Biological Evaluation of Reniochalistatins A-E and a Reniochalistatin E Analogue.</title>
<author><name sortKey="Zhou, Rong" sort="Zhou, Rong" uniqKey="Zhou R" first="Rong" last="Zhou">Rong Zhou</name>
<affiliation><nlm:affiliation>Department of Chemistry, Jinan University, Guangzhou, 510632, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Sun, Yueguang" sort="Sun, Yueguang" uniqKey="Sun Y" first="Yueguang" last="Sun">Yueguang Sun</name>
<affiliation><nlm:affiliation>Department of Chemistry, Jinan University, Guangzhou, 510632, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Li, Hangbin" sort="Li, Hangbin" uniqKey="Li H" first="Hangbin" last="Li">Hangbin Li</name>
<affiliation><nlm:affiliation>Department of Chemistry, Jinan University, Guangzhou, 510632, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Long, Weili" sort="Long, Weili" uniqKey="Long W" first="Weili" last="Long">Weili Long</name>
<affiliation><nlm:affiliation>Department of Chemistry, Jinan University, Guangzhou, 510632, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Liao, Xiaojian" sort="Liao, Xiaojian" uniqKey="Liao X" first="Xiaojian" last="Liao">Xiaojian Liao</name>
<affiliation><nlm:affiliation>Department of Chemistry, Jinan University, Guangzhou, 510632, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Feng, Pengju" sort="Feng, Pengju" uniqKey="Feng P" first="Pengju" last="Feng">Pengju Feng</name>
<affiliation><nlm:affiliation>Department of Chemistry, Jinan University, Guangzhou, 510632, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Xu, Shihai" sort="Xu, Shihai" uniqKey="Xu S" first="Shihai" last="Xu">Shihai Xu</name>
<affiliation><nlm:affiliation>Department of Chemistry, Jinan University, Guangzhou, 510632, China.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2018">2018</date>
<idno type="RBID">pubmed:30102451</idno>
<idno type="pmid">30102451</idno>
<idno type="doi">10.1002/cmdc.201800529</idno>
<idno type="wicri:Area/PubMed/Corpus">000985</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000985</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Synthesis and Biological Evaluation of Reniochalistatins A-E and a Reniochalistatin E Analogue.</title>
<author><name sortKey="Zhou, Rong" sort="Zhou, Rong" uniqKey="Zhou R" first="Rong" last="Zhou">Rong Zhou</name>
<affiliation><nlm:affiliation>Department of Chemistry, Jinan University, Guangzhou, 510632, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Sun, Yueguang" sort="Sun, Yueguang" uniqKey="Sun Y" first="Yueguang" last="Sun">Yueguang Sun</name>
<affiliation><nlm:affiliation>Department of Chemistry, Jinan University, Guangzhou, 510632, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Li, Hangbin" sort="Li, Hangbin" uniqKey="Li H" first="Hangbin" last="Li">Hangbin Li</name>
<affiliation><nlm:affiliation>Department of Chemistry, Jinan University, Guangzhou, 510632, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Long, Weili" sort="Long, Weili" uniqKey="Long W" first="Weili" last="Long">Weili Long</name>
<affiliation><nlm:affiliation>Department of Chemistry, Jinan University, Guangzhou, 510632, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Liao, Xiaojian" sort="Liao, Xiaojian" uniqKey="Liao X" first="Xiaojian" last="Liao">Xiaojian Liao</name>
<affiliation><nlm:affiliation>Department of Chemistry, Jinan University, Guangzhou, 510632, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Feng, Pengju" sort="Feng, Pengju" uniqKey="Feng P" first="Pengju" last="Feng">Pengju Feng</name>
<affiliation><nlm:affiliation>Department of Chemistry, Jinan University, Guangzhou, 510632, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Xu, Shihai" sort="Xu, Shihai" uniqKey="Xu S" first="Shihai" last="Xu">Shihai Xu</name>
<affiliation><nlm:affiliation>Department of Chemistry, Jinan University, Guangzhou, 510632, China.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">ChemMedChem</title>
<idno type="eISSN">1860-7187</idno>
<imprint><date when="2018" type="published">2018</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Anti-Infective Agents (chemical synthesis)</term>
<term>Anti-Infective Agents (chemistry)</term>
<term>Anti-Infective Agents (pharmacology)</term>
<term>Anti-Inflammatory Agents (chemical synthesis)</term>
<term>Anti-Inflammatory Agents (chemistry)</term>
<term>Anti-Inflammatory Agents (pharmacology)</term>
<term>Antineoplastic Agents (chemical synthesis)</term>
<term>Antineoplastic Agents (chemistry)</term>
<term>Antineoplastic Agents (pharmacology)</term>
<term>Cell Line, Tumor</term>
<term>Cyclization</term>
<term>Cyclooxygenase 1 (metabolism)</term>
<term>Cyclooxygenase 2 (metabolism)</term>
<term>Humans</term>
<term>Influenza A Virus, H3N2 Subtype (drug effects)</term>
<term>Molecular Structure</term>
<term>Peptides, Cyclic (chemical synthesis)</term>
<term>Peptides, Cyclic (chemistry)</term>
<term>Peptides, Cyclic (pharmacology)</term>
<term>Porifera (chemistry)</term>
<term>Solid-Phase Synthesis Techniques</term>
<term>Structure-Activity Relationship</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemical synthesis" xml:lang="en"><term>Anti-Infective Agents</term>
<term>Anti-Inflammatory Agents</term>
<term>Antineoplastic Agents</term>
<term>Peptides, Cyclic</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Anti-Infective Agents</term>
<term>Anti-Inflammatory Agents</term>
<term>Antineoplastic Agents</term>
<term>Peptides, Cyclic</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Cyclooxygenase 1</term>
<term>Cyclooxygenase 2</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Anti-Infective Agents</term>
<term>Anti-Inflammatory Agents</term>
<term>Antineoplastic Agents</term>
<term>Peptides, Cyclic</term>
</keywords>
<keywords scheme="MESH" qualifier="chemistry" xml:lang="en"><term>Porifera</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Influenza A Virus, H3N2 Subtype</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Cell Line, Tumor</term>
<term>Cyclization</term>
<term>Humans</term>
<term>Molecular Structure</term>
<term>Solid-Phase Synthesis Techniques</term>
<term>Structure-Activity Relationship</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The total synthesis of reniochalistatins A-E, along with a reniochalistatin E analogue (inverso-E) was successfully achieved through Fmoc-based solid-phase peptide synthesis and subsequent macrolactamization with PyBOP and DIEA. The biological activities of these reniochalistatins and a key linear peptide intermediate were systematically evaluated. Among these seven synthesized compounds, linear reniochalistatin B was found to have potent activity against several cancer cell lines not shown by the cyclic reniochalistatin B counterpart. In addition, linear reniochalistatin B was found to have antitubercular activity (IC<sub>50</sub>
=1.4 μm). Inverso-E possesses increasing cytotoxicity against the HeLa and LNCaP cell lines after simple alternation of the sequence of amino acids in reniochalistatin E. The results of these studies provide a feasible method to further investigate the structure-activity relationships (SARs) of reniochalistatins A-E.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30102451</PMID>
<DateCompleted><Year>2019</Year>
<Month>09</Month>
<Day>16</Day>
</DateCompleted>
<DateRevised><Year>2019</Year>
<Month>09</Month>
<Day>16</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1860-7187</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>13</Volume>
<Issue>20</Issue>
<PubDate><Year>2018</Year>
<Month>10</Month>
<Day>22</Day>
</PubDate>
</JournalIssue>
<Title>ChemMedChem</Title>
<ISOAbbreviation>ChemMedChem</ISOAbbreviation>
</Journal>
<ArticleTitle>Synthesis and Biological Evaluation of Reniochalistatins A-E and a Reniochalistatin E Analogue.</ArticleTitle>
<Pagination><MedlinePgn>2202-2207</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/cmdc.201800529</ELocationID>
<Abstract><AbstractText>The total synthesis of reniochalistatins A-E, along with a reniochalistatin E analogue (inverso-E) was successfully achieved through Fmoc-based solid-phase peptide synthesis and subsequent macrolactamization with PyBOP and DIEA. The biological activities of these reniochalistatins and a key linear peptide intermediate were systematically evaluated. Among these seven synthesized compounds, linear reniochalistatin B was found to have potent activity against several cancer cell lines not shown by the cyclic reniochalistatin B counterpart. In addition, linear reniochalistatin B was found to have antitubercular activity (IC<sub>50</sub>
=1.4 μm). Inverso-E possesses increasing cytotoxicity against the HeLa and LNCaP cell lines after simple alternation of the sequence of amino acids in reniochalistatin E. The results of these studies provide a feasible method to further investigate the structure-activity relationships (SARs) of reniochalistatins A-E.</AbstractText>
<CopyrightInformation>© 2018 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhou</LastName>
<ForeName>Rong</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>Department of Chemistry, Jinan University, Guangzhou, 510632, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Sun</LastName>
<ForeName>Yueguang</ForeName>
<Initials>Y</Initials>
<AffiliationInfo><Affiliation>Department of Chemistry, Jinan University, Guangzhou, 510632, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Li</LastName>
<ForeName>Hangbin</ForeName>
<Initials>H</Initials>
<AffiliationInfo><Affiliation>Department of Chemistry, Jinan University, Guangzhou, 510632, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Long</LastName>
<ForeName>Weili</ForeName>
<Initials>W</Initials>
<AffiliationInfo><Affiliation>Department of Chemistry, Jinan University, Guangzhou, 510632, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Liao</LastName>
<ForeName>Xiaojian</ForeName>
<Initials>X</Initials>
<AffiliationInfo><Affiliation>Department of Chemistry, Jinan University, Guangzhou, 510632, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Feng</LastName>
<ForeName>Pengju</ForeName>
<Initials>P</Initials>
<Identifier Source="ORCID">0000-0002-5470-0403</Identifier>
<AffiliationInfo><Affiliation>Department of Chemistry, Jinan University, Guangzhou, 510632, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Xu</LastName>
<ForeName>Shihai</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Department of Chemistry, Jinan University, Guangzhou, 510632, China.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2018</Year>
<Month>09</Month>
<Day>05</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Germany</Country>
<MedlineTA>ChemMedChem</MedlineTA>
<NlmUniqueID>101259013</NlmUniqueID>
<ISSNLinking>1860-7179</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000890">Anti-Infective Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010456">Peptides, Cyclic</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 1.14.99.1</RegistryNumber>
<NameOfSubstance UI="D051545">Cyclooxygenase 1</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 1.14.99.1</RegistryNumber>
<NameOfSubstance UI="D051546">Cyclooxygenase 2</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000890" MajorTopicYN="N">Anti-Infective Agents</DescriptorName>
<QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName>
<QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
<QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003500" MajorTopicYN="N">Cyclization</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051545" MajorTopicYN="N">Cyclooxygenase 1</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051546" MajorTopicYN="N">Cyclooxygenase 2</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053122" MajorTopicYN="N">Influenza A Virus, H3N2 Subtype</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015394" MajorTopicYN="N">Molecular Structure</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010456" MajorTopicYN="N">Peptides, Cyclic</DescriptorName>
<QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011161" MajorTopicYN="N">Porifera</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D060327" MajorTopicYN="N">Solid-Phase Synthesis Techniques</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">cyclic peptides</Keyword>
<Keyword MajorTopicYN="Y">macrolactamization</Keyword>
<Keyword MajorTopicYN="Y">proline</Keyword>
<Keyword MajorTopicYN="Y">reniochalistatins</Keyword>
<Keyword MajorTopicYN="Y">solid-phase peptide synthesis</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year>
<Month>08</Month>
<Day>06</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2018</Year>
<Month>8</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2019</Year>
<Month>9</Month>
<Day>17</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2018</Year>
<Month>8</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">30102451</ArticleId>
<ArticleId IdType="doi">10.1002/cmdc.201800529</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000985 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000985 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:30102451 |texte= Synthesis and Biological Evaluation of Reniochalistatins A-E and a Reniochalistatin E Analogue. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:30102451" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a SrasV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |